E-nitiate starts Phase 2 trial of oral QY201 in non-segmental vitiligo
The randomized, placebo-controlled study enters a field where JAK inhibitors and a rival Chinese oral candidate are already in Phase 3, with F-VASI at week 24 as the bar.
Executive Summary
- E-nitiate Biopharmaceuticals has opened a Phase 2 randomized, placebo-controlled trial of an oral tablet for non-segmental vitiligo, sized to detect a repigmentation signal against placebo over six months.
- The trial enters a non-segmental vitiligo field where other oral small molecules have already advanced to Phase 3, testing the same disease-activity endpoint this program will use at an earlier stage of development.
- The molecule's target and mechanism are not established in available records, so its differentiation from JAK inhibitors and other oral candidates already in the field cannot yet be assessed on mechanism.
- The sponsor's broader pipeline is small and mostly early-stage, making this trial the company's most advanced disclosed non-segmental vitiligo program.
The trial
The study is a multicenter, randomized, parallel-group, double-blind (quadruple-masked), placebo-controlled Phase 2 trial evaluating QY201 tablets in adults aged 18 to 65 with clinically diagnosed non-segmental vitiligo. It plans to enroll 200 patients across four arms at sites in China, with a primary completion date of December 31, 2026. The trial started enrolling on November 5, 2025, and remains in Recruiting status. NCT07712523A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental VitiligoNCT07712523
The endpoint
The registered primary endpoint measures the percentage change from baseline in Facial Vitiligo Area Scoring Index (F-VASI), a validated measure of facial depigmentation, after 24 weeks of treatment, compared between the QY201 arms and placebo. Patients who stop treatment early for lack of efficacy, or who take prohibited concomitant medications that would interfere with the efficacy read, are counted as treatment failures under the protocol. No efficacy or safety data have posted yet, so the trial's information value at this stage is the design itself: a placebo-controlled, quadruple-masked structure built to produce a decision-grade repigmentation readout at week 24. NCT07712523A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental VitiligoNCT07712523
The competitive field
Non-segmental vitiligo already has two same-indication, same-modality programs at a later stage than QY201: AbbVie's upadacitinib, an oral JAK inhibitor, is in a Phase 3 trial (NCT06118411) with adverse-event monitoring as its primary outcome and a completion date of March 2028, and Beijing InnoCare Pharma Tech's ICP-332 is in Phase 3 (NCT07047612) using the same F-VASI-at-week-24 measure QY201 has adopted, with completion targeted for April 2029. A third oral candidate, Shanghai Longwood Biopharmaceuticals' LW402, is also positioned in non-segmental vitiligo and has not yet begun recruiting. QY201's target and mechanism are not established in available records, so it cannot be placed relative to these programs on mechanism; what is comparable is that all three share oral, small-molecule delivery and are being tested against the same F-VASI framework.
Field shape
The broader non-segmental vitiligo and vitiligo trial set includes eight active programs spanning Phase 1 through Phase 3, with AbbVie's upadacitinib carrying the largest enrollment at 614 patients and InnoCare's ICP-332 at 603. With one program already reporting adverse-event data in Phase 3 and a second running the same primary measure QY201 uses, a within-class disease-activity mechanism for oral non-segmental vitiligo treatment is being tested in parallel by multiple sponsors rather than validated by any single one yet. For QY201's Phase 2 result to inform that broader question, it would need to show a F-VASI improvement over placebo large enough to justify advancing into the same late-stage territory its peers already occupy.
Sponsor and portfolio
E-nitiate Biopharmaceuticals has a total of seven trials on record, with one currently recruiting, one enrolling by invitation, two completed, and three carrying an unknown status. This is the sponsor's only active trial in non-segmental vitiligo and its only disclosed Phase 2 program at this stage.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.